Japan Lifeline (7575) Q1 2027 earnings summary

Executive summary

• Net sales for Q1 FY2027 reached ¥15,904mn, up 8.8% YoY, with strong growth in core and new therapeutic areas.

• Operating profit declined 9.4% YoY to ¥2,965mn due to increased R&D and personnel costs, resulting in an 18.6% margin.

• Net income rose 0.3% YoY to ¥2,309mn, supported by reversal of allowance for doubtful accounts and FX gains.

• All major business areas except Cardiac Rhythm Management posted sales growth, with Neurovascular and Gastrointestinal segments achieving double-digit increases.

• FY2027 guidance for sales and profit remains unchanged; dividend forecast revised upward to include a commemorative payout.

Financial highlights

• Gross profit increased to ¥9,174mn (57.7% margin), but gross margin declined due to higher manufacturing costs.

• SG&A expenses rose by ¥711mn YoY, reflecting increased personnel and R&D spending.

• Proprietary product sales mix improved to 57.2% (from 55.6% YoY); international sales mix rose to 2.7%.

• Basic and diluted EPS was ¥32.93, up ¥0.08 YoY.

• Comprehensive income was ¥2,330mn, up 10.0% YoY.

Outlook and guidance

• Full-year forecast reaffirmed: Net sales ¥63,200mn (+6.8% YoY), operating profit ¥10,700mn (−15.1% YoY), net income ¥8,000mn (−14.4% YoY), EPS ¥114.02.

• Dividend forecast revised to ¥81/share, including a ¥25 interim commemorative dividend for the 25th anniversary.

• Sales in EP/Ablation and Neurovascular expected to remain strong, offsetting weaker Cardiac Rhythm Management.

• Net sales, operating profit, and net income are all tracking ahead of pace to meet full-year FY2027 guidance.

• Business outlook expects continued growth in EP/Ablation, Cardiovascular, Neurovascular, and Gastrointestinal segments, with some headwinds in Cardiac Rhythm Management due to competitor products.